Telomir Pharmaceuticals, Inc. (TELO)

6.54 +0.52 (+8.64%) At close: 04:00PM EDT

Telomir Pharmaceuticals, Inc.

855 N Wolfe Street
Suite 601
Baltimore, MD 21205
United States
(737)-289-0835
https://telomirpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christopher C. Chapman Jr., M.D.	Co-Founder, Chairman & CEO	N/A	N/A	1953

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Corporate governance

Telomir Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.